UC Irving Secures $2m—Joins CIRM Cell & Gene Manufacturing Network in the Golden State

The University of Irvine (UCI) received a two-year, $2 million grant as part of its inclusion in the California Institute for Regenerative Medicine Cell and Gene Therapy Manufacturing Network. TrialSite has reported on the trend involving cell therapy and gene therapy involving manufacturing of advanced, novel such therapies at the point of care—the major academic hospitals that have the expertise, intellectual capital, technology, infrastructure and facilities to produce some of the world’s most novel therapies. With an aim on acceleration of commercialization of life-saving novel cell and gene therapies, as well as advancing industry standards, bolstering quality in this critical, unfolding endeavor, while importantly, developing the human capital involved in this pursuit, the statewide network includes other cell and gene therapy manufacturing sites including UCLA, USC, Cedars-Sinai Medical Center, City of Hope, UC San Diego, UC Davis, Stanford University and UC San Francisco.

Cell & Gene Therapy Manufacturing @UCI